Optimizing future treatment of enterococcal infections: attacking the biofilm?

Trends Microbiol. 2012 Jan;20(1):40-9. doi: 10.1016/j.tim.2011.11.001. Epub 2011 Dec 12.

Abstract

Enterococcus faecalis and Enterococcus faecium are among the leading causative agents of nosocomial infections and are infamous for their resistance to many antibiotics. They cause difficult-to-treat infections, often originating from biofilm-mediated infections associated with implanted medical devices or endocarditis. Biofilms protect bacteria against antibiotics and phagocytosis, and physical removal of devices or infected tissue is often needed but is frequently not possible. Currently there are no clinically available compounds that disassemble biofilms. In this review we discuss all known structural and regulatory genes involved in enterococcal biofilm formation, the compounds directed against biofilm formation that have been studied, and potentially useful targets for future drugs to treat enterococcal biofilm-associated infections.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Biofilms / drug effects*
  • Biofilms / growth & development
  • Cross Infection / drug therapy
  • Cross Infection / microbiology
  • Enterococcus faecalis / genetics
  • Enterococcus faecalis / isolation & purification*
  • Enterococcus faecalis / pathogenicity
  • Enterococcus faecium / genetics
  • Enterococcus faecium / isolation & purification*
  • Enterococcus faecium / pathogenicity
  • Gene Expression Regulation, Bacterial
  • Gram-Positive Bacterial Infections / drug therapy*
  • Gram-Positive Bacterial Infections / microbiology*
  • Humans
  • Virulence Factors / genetics

Substances

  • Anti-Bacterial Agents
  • Virulence Factors